GlassScriptPhysician profile
Ram Lalchandani
NPI 1114993813
$5,952.71
in general payments reported to CMS, 2019-2025
37 companies · $429 in 2025
The $429 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $248 · 2021: $1,374 · 2022: $525 · 2023: $400 · 2024: $2,408 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726 · Travel and Lodging: $1,262 · Education: $216 · Gift: $33.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.90 |
| Travel and Lodging | $1,262.39 |
| Education | $215.75 |
| Gift | $33.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $1,697.49 | 2024 | |
| Pfizer INC. | $658.40 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $346.47 | 2020-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $337.89 | 2019-2024 | Erleada |
| Astellas Pharma US INC | $294.37 | 2019-2023 | Padcev |
| Genentech USA, INC. | $261.14 | 2019-2025 | Polivy, Tecentriq, Alecensa |
| Lilly USA, LLC | $230.29 | 2020-2025 | Verzenio |
| Amgen INC. | $193.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $190.72 | 2020-2025 | |
| Seagen INC. | $174.99 | 2021 | |
| Kite Pharma, INC. | $152.69 | 2020-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $146.45 | 2021 | |
| Celgene Corporation | $139.15 | 2023-2025 | Reblozyl, Pomalyst |
| Servier Pharmaceuticals LLC | $127.22 | 2022-2025 | |
| Daiichi Sankyo INC. | $125.22 | 2024-2025 | Enhertu, Injectafer |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Lalchandani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.